Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
Go back to Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies| (NASDAQ: DARE) | Delayed: 2.08 -0.09 (4.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.17 | 52 Week High | $ | |||
| Open | $2.20 | 52 Week Low | $ | |||
| Day High | $2.21 | P/E | N/A | |||
| Day Low | $2.07 | EPS | $ | |||
| Volume | 179,593 | |||||
